Edesa Biotech (EDSA) Total Current Liabilities (2013 - 2026)
Edesa Biotech (EDSA) posted Total Current Liabilities of $756163.0 for Q4 2025, down 29.89% sequentially from $1.1 million in Q3 2025, and down 60.21% YoY from $1.9 million in Q4 2024.
Edesa Biotech (EDSA) Total Current Liabilities (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Total Current Liabilities for 13 years, with the latest figure at $756163.0 in Q4 2025.
- Quarterly Total Current Liabilities fell 60.21% year-over-year to $756163.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $756163.0 (down 60.21% YoY) and the FY2025 annual result came in at $1.1 million, down 41.15% from the prior year.
- Total Current Liabilities retreated to $756163.0 in Q4 2025 per EDSA's latest filing, from $1.1 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $5.7 million in Q2 2022 and troughed at $672674.0 in Q2 2025.
- A 5-year average of $2.0 million and a median of $1.8 million in 2021 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2021 and 2023: Total Current Liabilities surged 698.04% in 2021, then plunged 72.97% in 2023.
- Over 5 years, Total Current Liabilities stood at $1.7 million in 2021, then retreated by 26.7% to $1.3 million in 2022, then surged by 55.18% to $2.0 million in 2023, then retreated by 4.36% to $1.9 million in 2024, then slumped by 60.21% to $756163.0 in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $756163.0, $1.1 million, and $672674.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 630.93 Mn |
| 10 | Edesa Biotech | 41.43 Mn | 41.43 Mn | - | 3.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.91 Mn |
| Dec 31, 2025 | 756,163.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 672,674.00 |
| Mar 31, 2025 | 914,701.00 |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 2.36 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 1.99 Mn |
| Sep 30, 2023 | 1.82 Mn |
| Jun 30, 2023 | 1.53 Mn |
| Mar 31, 2023 | 1.56 Mn |
| Dec 31, 2022 | 1.28 Mn |
| Sep 30, 2022 | 2.14 Mn |
| Jun 30, 2022 | 5.66 Mn |
| Mar 31, 2022 | 3.34 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.46 Mn |
| Jun 30, 2021 | 983,467.00 |